Pfizer expects to restart production at tornado hit plant by early Q4
North Carolina: Pfizer said on Monday it expects to restart production at its North Carolina plant by the beginning of the fourth quarter of 2023 as it seeks to repair tornado damage to one of the world's largest sterile injectable drug facilities.
The facility was struck by a tornado on July 19, and Pfizer had earlier said some drugs, including painkiller fentanyl, could see a supply disruption. Pfizer has since placed limits on how much supply of those drugs its customers can buy.
Most of the damage from the tornado was to a warehouse, and not production facilities, but Pfizer had indicated it would be a monumental task to repair the damage.
On Monday, Pfizer said a temporary warehouse location has been secured to accommodate product storage. The company added it had started releasing units of product that were not impacted by the tornado to distribution centers.
Pfizer's sterile injectable products include anesthesia, painkillers and anti-infective medicines for use in hospitals.
The number of U.S. drug shortages is already near a 10-year high, according to the American Society of Health-System Pharmacists.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.